Azurity Pharmaceuticals, Inc.

September 15-21, 2024 WARRENVILLE, Ill., Sept. 9, 2024 /PRNewswire/ -- The MAGIC Foundation and their sponsors Ascendis Pharma, Azurity Pharmaceuticals, Novo Nordisk, and Pfizer, are proud to announce the annual Children's Growth Awareness Week, taking place from September 15-21, 2024. This important event highlights the critical role that tracking physical growth plays in monitoring a child's overall health. Abnormal growth patterns can be an early indicator of an underlying medical condition, making it essential for parents and caregivers to pay close attention to their child's growth. Continue Reading Children's Growth Awareness Week: Why Growth Awareness Matters Why Growth Awareness Matters Physical growth is one of the most significant indicators of a child's health. A delay in growth or even accelerated growth can signal underlying medical disorders that may require intervention. Tracking growth over time helps identify trends that might otherwise go unnoticed, ensuring that children are growing at the proper rate for their age and development. Mary Andrews, Co-Founder of The MAGIC Foundation explains, "If, as parents, we understand how important annual measurements are, and what they can reveal about our child's health, we know to obtain medical care early, instead of waiting to see if they 'outgrow' a problem. Abnormal growth is a major indicator of a child's overall health. The goal is to educate parents and give doctors more time to intervene if needed, to help the child before permanent damage occurs." Growth Awareness Week serves as an additional opportunity to educate parents, caregivers, and anyone involved in the lives of children to bring awareness to the topic of growth disorders. As MAGIC puts it, "Children have a short time to grow and a lifetime to live with the results." The MAGIC Foundation is a charitable non-profit organization dedicated to providing support services to families of children afflicted with a wide variety of chronic and/or critical disorders, syndromes, and diseases that affect a child's growth. We urge everyone to spread awareness about the importance of monitoring children's growth. Visit () to learn more about how you can educate yourself, family, friends, coworkers and community. If you have concerns about your child's growth, be sure to speak to their doctor. For more information, please contact The MAGIC Foundation's national office at [email protected] or (800) 362-4423. Media Contact: Courtney Rivard 6308368200 [email protected] SOURCE The MAGIC Foundation

Nymalize is indicated for use in adult patients with subarachnoid haemorrhage from ruptured intracranial berry aneurysms. Credit: Radiological imaging/Shutterstock. Azurity Pharmaceuticals’ Nymalize (nimodipine) oral solution in a 30mg/5ml prefilled ENFit syringe has received US Food and Drug Administration (FDA) approval. The ready-to-use prefilled syringe offers an additional layer of security for both patients and healthcare professionals when administering medication. The oral solution in the prefilled ENFit syringe offers an effective alternative for adult subarachnoid haemorrhage patients who are unable to swallow capsules. The adoption of ENFit connectors, which are recommended by the FDA, is said to be on the rise, with around 60% of acute care facilities in the US making the switch from traditional nasogastric tubing. Nymalize improves neurological outcomes by reducing the incidence and severity of ischemic deficits in adults with subarachnoid haemorrhage from ruptured intracranial berry aneurysms. See Also: RegenxBio touts positive data for rare disease drug RGX-121 Ocaliva approval in Europe withdrawn following data re-assessment It is suitable for patients across a range of post-ictus neurological conditions, classified from Hunt and Hess Grades I to V. The Nymalize prefilled ENFit syringes (30 mg/5 ml), along with prefilled oral syringes (30 mg/5 ml and 60 mg/10 ml) and 8 oz (237 ml) bottles will soon be available for order through pharmaceutical wholesalers. Azurity Pharmaceuticals CEO Richard Blackburn stated: “Patients are our priority, and our purpose is to bring them new formulations and delivery systems that help them benefit from established medicines. “Delivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure, reliable drug administration through standardisation.” In September 2022, the FDA granted approval for Azurity’s Konvomep (omeprazole and sodium bicarbonate for oral suspension) to treat active benign gastric ulcers .

WOBURN, Mass., Sept. 3, 2024 /PRNewswire/ -- Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Nymalize® (nimodipine) oral solution in a 30 mg/5 mL prefilled ENFit® syringe. "Patients are our priority, and our purpose is to bring them new formulations and delivery systems that help them benefit from established medicines," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "Delivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure, reliable drug administration through standardization." The Nymalize 30 mg/5 mL prefilled ENFit syringe may provide an additional layer of security for patients and healthcare professionals administering medication.1-3 ENFit connectors are recommended by the FDA and widespread adoption of ENFit has begun to replace traditional nasogastric tubing.4-6 Approximately 60% of all acute care facilities in the USA have adopted ENFit.5 Nymalize offers an effective alternative to capsule extraction for adult subarachnoid hemorrhage patients who cannot swallow capsules. Nymalize is available in ready-to-use prefilled ENFit syringes (30 mg/5 mL), prefilled oral syringes (30 mg/5 mL and 60 mg/10 mL) and in 8 oz (237 mL) bottles. Nymalize may help reduce the risk of fatal medication errors associated with nimodipine capsule extraction. Nymalize is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I–V). The Nymalize prefilled ENFit syringe will be available to order through a pharmaceutical wholesaler in the coming weeks. For important safety information and full prescribing information, please visit . About Azurity Pharmaceuticals, Inc. Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. We supply a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective, and oncology medicines. Many of our medicines are dose-form innovations for patients with needs that are not met by other available products. Our medicines have benefited millions of people. For more information, visit . References: 1. Stay Connected User Benefits of the ENFit® Enteral Feeding System . 2. U.S. Food & Drug Administration, Examples of Medical Device Misconnections . 3. Stay Connected ENFit® Pharmacy Resource . 4. FDA. The FDA encourages use of enteral device connectors that reduce risk of misconnection and patient injury. Accessed May 1, 2024. 5. ENFIT Global Conversion Updates & Map. Stay Connected® by GEDSA. 2023. Accessed June 26, 2024. 6. GEDSA US conversion rates flyer 2023. Stay Connected® by GEDSA. 2023. Accessed June 26, 2024. Nymalize® is a registered trademark of Azurity Pharmaceuticals, Inc. ENFit® is a registered trademark of Global Enteral Device Supplier Association, Inc. SOURCE Azurity Pharmaceuticals, Inc.